SAN DIEGO, CA – March 31, 2020 – The National Institute of Health (NIH) and its subdivision,  the  National Center for Advancing Translational Sciences (NCATS), recently awarded AnaBios a 12-month Small Business Innovation Research (SBIR) grant in the amount of $1,132,289 to develop a novel technology to measure physiological parameters in adult human primary cardiomyocytes. The new technology will allow AnaBios to evaluate thousands of compounds per year in support of medicinal chemistry efforts and preclinical cardiac risk assessment in a truly translational assay.

Identifying the cardiotoxicity risk of a drug in advance of clinical studies remains a major challenge for pharmaceutical companies and regulators. The research project  funded by NIH/NCATS aims at developing a robust and cost-effective laboratory platform based on adult human primary cardiomyocytes and a novel instrument recently developed at AnaBios. It is expected that the products and services resulting from this project will enable the early identification of potentially cardiotoxic drugs and further, greatly accelerate the quest for novel therapeutics for the treatment of cardiac disorders, such as heart failure and atrial fibrillation.

“AnaBios is honored to receive this important grant from the NIH in support of our continued effort to innovate preclinical cardiac research,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “We believe that the successful outcome of this project will result in critical improvements of the drug development paradigm, which will ultimately lead to novel effective and safe drugs for patients.”

The award sited in this press release is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number R44TR003162. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

 

About AnaBios

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, pain and itch. In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry. For more information about AnaBios, visit https://anabios.com.